Description
HBM4003 is an investigational medication currently being studied in clinical trials. It is being evaluated in combination with other investigational drugs like Toripalimab for patients with advanced neuroendocrine tumors (NET) and other solid tumors. The goal of these early-phase trials (Phase 1) is to determine the safety and tolerability of HBM4003, and to find the best dose for further studies. While the specific mechanism of action is being investigated, HBM4003 is being explored as a potential treatment option for various cancers. Currently, there is limited information available specifically about its use or effectiveness in colorectal cancer, as the provided trial focuses on NET and other solid tumors. More research is needed to understand its potential role in treating colorectal cancer.
Mechanism of Action
The specific way HBM4003 works (its mechanism of action) is still under investigation in clinical trials. It is being studied in combination with Toripalimab, another investigational drug. The trials aim to assess safety and determine appropriate dosages for future research.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.